Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24 ‐week treatment‐free follow‐up

Conclusion52 weeks of mepolizumab treatment is associated with sustained clinical benefits up to 24 weeks after discontinuation in patients with severe CRSwNP, which should be considered by physicians when making treatment decisions.This article is protected by copyright. All rights reserved

Source: International Forum of Allergy and Rhinology - June 23, 2023 Category: Allergy & Immunology Authors: Martin Desrosiers, Zuzana Diamant, Paolo Castelnuovo, Peter W Hellings, Joseph K Han, Anju T Peters, Jared Silver, Steven G Smith, Abigail Fuller, Ana R Sousa, Robert H Chan, Philippe Gevaert Tags: ORIGINAL ARTICLE Source Type: research